GLP-1 also has extra-pancreatic effects on satiety, food intake, energy metabolism and cardiovascular system and GLP-1 receptor agonism has become a mainstay in the management of type 2 diabetes mellitus, particularly in patients with atherosclerotic disease (American Diabetes Association, 2018). This evidence concerns the gene GLP1R and diabetes mellitus.